Capricor's DMD Cell Therapy Has HOPE, But Market Is Unsure
Capricor will start a Phase II trial in the first quarter of 2018 for its regenerative cell therapy CAP-1002 in Duchenne muscular dystrophy following positive results in an early-stage trial – the stem cell product was dropped by Capricor's big pharma partner Johnson & Johnson earlier this year.
You may also be interested in...
California biotech says it will move forward with knowledge and expertise gained through the failed partnership. Capricor hopes to re-partner CAP-1002 for cardiovascular indications, while continuing the candidate’s DMD development itself.
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.